Detalles de la búsqueda
1.
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Circulation
; 135(7): 648-655, 2017 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27881569
2.
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
Am Heart J
; 198: 84-90, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29653652
3.
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Am Heart J
; 185: 93-100, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28267480
4.
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Circulation
; 116(2): 180-7, 2007 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-17576867
5.
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial.
TH Open
; 2(1): e16-e24, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31249924
6.
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
J Am Heart Assoc
; 6(7)2017 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28698258
7.
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest
; 126(3 Suppl): 401S-428S, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15383479
Resultados
1 -
7
de 7
1
Próxima >
>>